Clinical Trial

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-16; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-01
Trial Details
NCT Number NCT07187778
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 10 participants
Start Date 2025-12-19
Primary Completion 2027-07-19 (estimated)
Study Completion 2029-07-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-07